122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology…
122 Patients Enrolled in Single-arm IDE Study; 30-Day Follow-upLATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology…
Eliminate data silos and streamline workflows to improve operational efficiencySAN DIEGO--(BUSINESS WIRE)--Seqster PDM, Inc. ("SEQSTER") , the industry leading patient-centric…
Eliminate data silos and streamline workflows to improve operational efficiencySAN DIEGO--(BUSINESS WIRE)--Seqster PDM, Inc. ("SEQSTER") , the industry leading patient-centric…
Atopic Dermatitis (AD) trial is the second KT-474 Phase 2 clinical trial to begin enrolling patients this quarter following trial…
To register for the webinar, click hereSAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a…
The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to…
LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient…
WALTHAM, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the…
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug…